Cambridge's AI-Designed Vaccine Enters Human Trials, Targets All Coronaviruses
First AI-designed vaccine tested in humans shows promise against future pandemics.
Deep Dive
Researchers at the University of Cambridge have developed what they describe as the world's first AI-designed vaccine, which has now been tested in people for the first time. The DNA-based vaccine targets stable features across the sarbecovirus family—including SARS, COVID-19, and bat coronaviruses—with the goal of providing broad protection. It uses needle-free delivery via high-pressure liquid, and DNA vaccines are generally more stable than mRNA vaccines, making them easier to store and transport.
Key Points
- AI designed the vaccine's key component by analyzing conserved genetic regions across the sarbecovirus family, including SARS and COVID-19.
- DNA-based formulation offers greater stability and easier storage than mRNA, with needle-free high-pressure delivery.
- Human trials show safety and immune response; could lead to a single vaccine against all current and future coronaviruses.
Why It Matters
Could enable rapid, universal protection against emerging viral threats, transforming pandemic preparedness and response.